Collegium Pharmaceutical, Inc. (COLL)
25.35
-1.09
(-4.12%)
USD |
NASDAQ |
Aug 28, 16:00
25.35
0.00 (0.00%)
After-Hours: 18:01
Collegium Pharmaceutical Cash from Operations (Quarterly) : 71.32M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 71.32M |
| March 31, 2026 | 57.11M |
| December 31, 2025 | 123.05M |
| September 30, 2025 | 78.44M |
| June 30, 2025 | 72.44M |
| March 31, 2025 | 55.40M |
| December 31, 2024 | 84.64M |
| September 30, 2024 | -8.999M |
| June 30, 2024 | 67.40M |
| March 31, 2024 | 61.94M |
| December 31, 2023 | 73.34M |
| September 30, 2023 | 74.02M |
| June 30, 2023 | 99.72M |
| March 31, 2023 | 27.67M |
| December 31, 2022 | 66.32M |
| September 30, 2022 | 42.77M |
| June 30, 2022 | 40.45M |
| March 31, 2022 | -25.32M |
| December 31, 2021 | 36.20M |
| September 30, 2021 | 17.25M |
| June 30, 2021 | 29.54M |
| March 31, 2021 | 20.57M |
| December 31, 2020 | 22.58M |
| Date | Value |
|---|---|
| September 30, 2020 | 34.18M |
| June 30, 2020 | 43.85M |
| March 31, 2020 | -6.669M |
| December 31, 2019 | 15.66M |
| September 30, 2019 | 6.069M |
| June 30, 2019 | 14.63M |
| March 31, 2019 | -8.569M |
| December 31, 2018 | 42.29M |
| September 30, 2018 | 41.83M |
| June 30, 2018 | 55.60M |
| March 31, 2018 | 29.66M |
| December 31, 2017 | -13.30M |
| September 30, 2017 | -12.57M |
| June 30, 2017 | -17.47M |
| March 31, 2017 | -23.69M |
| December 31, 2016 | -23.29M |
| September 30, 2016 | -19.41M |
| June 30, 2016 | -20.84M |
| March 31, 2016 | -11.52M |
| December 31, 2015 | -6.604M |
| September 30, 2015 | -6.536M |
| June 30, 2015 | -4.411M |
| March 31, 2015 | -4.016M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Innoviva, Inc. | 51.97M |
| Zevra Therapeutics, Inc. | 17.03M |
| Supernus Pharmaceuticals, Inc. | -4.81M |
| Indivior Pharmaceuticals, Inc. | 228.52M |
| Crinetics Pharmaceuticals, Inc. | -94.19M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -502.59M |
| Cash from Financing (Quarterly) | 292.09M |
| Free Cash Flow | 328.28M |
| Free Cash Flow Per Share (Quarterly) | 2.182 |
| Free Cash Flow to Equity (Quarterly) | -217.36M |
| Free Cash Flow to Firm (Quarterly) | 92.54M |
| Free Cash Flow Yield | 34.07% |